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Abstract: The International Federation of Clinical Chem-
istry and Laboratory Medicine (IFCC) formed a Task Force 
on the Application of Cardiac Bio-markers (TF-CB) in 
2008, re-designated in 2018 as a committee (C-CB), to pro-
duce educational materials on cardiac biomarkers. Estab-
lished in June 2017, definitive tables covering the majority 
of high-sensitivity, contemporary and point-of-care (POC) 
cTn assays have been developed by the C-CB and are avail-
able on the IFCC website. These tables provide extensive 
information about assays’ analytical characteristics and 
encompass information on diagnostic discriminants, 
particularly the 99th percentiles, as provided by the 
manufacturers.
Keywords: 99th percentiles; cardiac troponin; education; 
high sensitivity assays; myocardial injury; point-of-care.
The Global Task Force for Fourth Universal Definition of 
Myocardial Infarction (MI) utilizes cardiac troponin (cTn) 
as the standard biomarker for the detection of myocardial 
injury [1]. An increased cTn concentration above the upper 
reference limit (URL) defines myocardial injury, with cTn 
URLs specified as sex-specific 99th percentiles of a normal 
healthy reference population, defined by sex, age, racial 
and ethnic diversity [1–4]. Prior to 2000, the definition 
of MI utilized a different diagnostic discriminant, the 
97.5th percentile of a reference population, for a ‘cardiac 
enzyme’, typically total creatine kinase (CK) or its MB iso-
enzyme (CK-MB) [5].
When first introduced into routine clinical practice, 
cTn assays were evaluated against the WHO diagnostic 
criteria for MI as the diagnostic gold standard. Using 
the WHO criteria as the diagnostic standard resulted in 
a relatively high diagnostic discriminant, typically 10–50 
times the cTn 99th percentile. Shortly after, the redefini-
tion of MI guidelines endorsed the preferred diagnostic 
discriminant as cTn, with a statement that cTn assays 
should ideally have a 10% coefficient of variation (CV) at 
the assay’s 99th percentile URL concentration [6]. Assays 
were considered to be clinically acceptable if they had a 
%CV at the 99th percentile ≤20%, as patients would not 
be misclassified at this concentration [7]. Introduction 
of cTn assays into routine clinical use was accompanied 
by a range of different proposed diagnostic URLs for the 
diagnosis of MI, likely due to the misunderstanding of 
the intent and recommendations within the guidelines. 
Surveys of laboratory practice revealed that there was 
still use of a range of biomarkers other than cTn and a 
great deal of uncertainty as to what diagnostic URL (WHO 
equivalent, 10% or 20% CV concentration, or the 99th 
percentile) was appropriate [8].
The International Federation of Clinical Chemistry 
and Laboratory Medicine (IFCC) formed a Task Force 
on the Application of Cardiac Bio-markers (TF-CB) in 
2008, re-designated in 2018 as a committee (C-CB), to 
produce educational materials on cardiac biomark-
ers [3–5]. Since the 2007  survey [2–4], there has been 
progressive improvement in assay analytical sensitiv-
ity, culminating in the development and global clini-
cal implementation of high-sensitivity (hs) cTn assays 
[2–4]. Subsequent surveys, most recently in 2016, have 
shown that although there has been a shift to cTn as the 
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preferred and primary biomarker, there remains a lack 
of a consistent approach to the interpretation of cTn 
measurements [9]. Although the IFCC C-CB has defined 
the analytical characteristics to define ‘high sensitivity’, 
there also continues to be confusion as to what defines 
an hs-cTn assay and how to optimally use hs-cTn assays 
clinically.
The current environment is partly due to both the 
rapid pace in assay development and to the legacy of 
the varied range of diagnostic URLs for MI. The IFCC 
C-CB seeks to address the broader educational needs of 
the laboratory and clinical community and to provide 
authoritative, explanatory reference documents for 
global widespread use. The C-CB has academic, clini-
cal and industry membership and works collaboratively 
with other clinical and laboratory medicine groups, 
such as the European Federation of Laboratory Medi-
cine (EFLM) and the Academy of the American Associa-
tion of Clinical Chemists (AACC). To date, several peer 
reviewed manuscripts have been produced to explain 
the concept of hs-cTn assays [2, 3]. The top eight analyti-
cal and top three clinical key components for the imple-
mentation of hs-cTn assays have been summarized as 
educational aids on a poster and a mouse pad and are 
currently available for distribution (poster) from by the 
IFCC if desired.
Established in June 2017, definitive tables covering 
the majority of high-sensitivity (Table 1), contemporary 
(Table 2) and point-of-care (POC) (Table 3) cTn assays 
have been developed by the C-CB and are available on 
the IFCC website [10–12]. These tables provide extensive 
information about assays’ analytical characteristics and 
encompass information on diagnostic discriminants, par-
ticularly the 99th percentiles, as provided by the manu-
facturers. In addition, a table that addresses the effects of 
hemolysis and biotin on cTn assays has been published 
[13] and posted to the IFCC website [14]. All tables will be 
updated on a quarterly basis. Further, tables summarizing 
analytical characteristics of natriuretic peptides (NP) [15] 
and effects of hemolysis and biotin on NP assays [16] are 
also found on the website. An educational document for 
NPs, paralleling the cTn document, is under development 
by the C-CB.
A series of industry sponsored workshops are being 
planned at major congresses, and started with the 2018 
AACC annual meeting in Chicago. Most importantly, the 
C-CB wishes to encourage educational feedback from the 
laboratory and clinical communities on what they and 
their clinical colleagues find challenging in routine clini-
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